These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33027815)

  • 1. A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
    Peereboom DM; Ye X; Mikkelsen T; Lesser GJ; Lieberman FS; Robins HI; Ahluwalia MS; Sloan AE; Grossman SA
    Neurosurgery; 2021 Jan; 88(2):246-251. PubMed ID: 33027815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
    Diaz-Padilla I; Wilson MK; Clarke BA; Hirte HW; Welch SA; Mackay HJ; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L; Liu G; Zhou C; Blattler C; Ivy SP; Oza AM
    Gynecol Oncol; 2015 May; 137(2):216-22. PubMed ID: 25769658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
    Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
    Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
    Xu R; Shimizu F; Hovinga K; Beal K; Karimi S; Droms L; Peck KK; Gutin P; Iorgulescu JB; Kaley T; DeAngelis L; Pentsova E; Nolan C; Grommes C; Chan T; Bobrow D; Hormigo A; Cross JR; Wu N; Takebe N; Panageas K; Ivy P; Supko JG; Tabar V; Omuro A
    Clin Cancer Res; 2016 Oct; 22(19):4786-4796. PubMed ID: 27154916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
    Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
    Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
    De Jesus-Acosta A; Laheru D; Maitra A; Arcaroli J; Rudek MA; Dasari A; Blatchford PJ; Quackenbush K; Messersmith W
    Invest New Drugs; 2014 Aug; 32(4):739-45. PubMed ID: 24668033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
    Pan E; Supko JG; Kaley TJ; Butowski NA; Cloughesy T; Jung J; Desideri S; Grossman S; Ye X; Park DM
    J Neurooncol; 2016 Dec; 130(3):571-579. PubMed ID: 27826680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.
    Kristoffersen K; Nedergaard MK; Villingshøj M; Borup R; Broholm H; Kjær A; Poulsen HS; Stockhausen MT
    Cancer Biol Ther; 2014 Jul; 15(7):862-77. PubMed ID: 24755988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
    Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
    Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
    Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
    J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.
    da Fonseca CO; Simão M; Lins IR; Caetano RO; Futuro D; Quirico-Santos T
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):287-93. PubMed ID: 20401670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
    Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M
    Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
    Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
    J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
    Bloch O; Crane CA; Fuks Y; Kaur R; Aghi MK; Berger MS; Butowski NA; Chang SM; Clarke JL; McDermott MW; Prados MD; Sloan AE; Bruce JN; Parsa AT
    Neuro Oncol; 2014 Jan; 16(2):274-9. PubMed ID: 24335700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
    Sardesai S; Badawi M; Mrozek E; Morgan E; Phelps M; Stephens J; Wei L; Kassem M; Ling Y; Lustberg M; Stover D; Williams N; Layman R; Reinbolt R; VanDeusen J; Cherian M; Grever M; Carson W; Ramaswamy B; Wesolowski R
    Invest New Drugs; 2020 Oct; 38(5):1400-1410. PubMed ID: 31953695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch.
    Floyd DH; Kefas B; Seleverstov O; Mykhaylyk O; Dominguez C; Comeau L; Plank C; Purow B
    Neuro Oncol; 2012 Oct; 14(10):1215-26. PubMed ID: 22962413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
    Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
    Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.